Zydus Pharmaceuticals (USA) Inc. is recalling various strengths of Oxybutynin Chloride Extended-Release Tablets (oxybutynin), a medication used to treat overactive bladder. The recall was initiated because the tablets failed dissolution testing during long-term stability checks. This defect means the medication might not release into the body at the correct rate, which could make the treatment less effective. No injuries or adverse health events have been reported at this time.
If the medication fails to dissolve as intended, the patient may not receive the proper dose of medicine over time, potentially leading to a return of urinary symptoms like urgency or frequency. No incidents or injuries have been reported to the company as of the recall date.
You have 2 options:
Manufactured by Cadila Healthcare Ltd, Baddi, India.
Manufactured by Cadila Healthcare Ltd, Baddi, India.
Manufactured by Cadila Healthcare Ltd, Baddi, India.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.